RxDoctor Payments DataLook up a doctor →

Mazen Khalil, MD

Hematology & Oncology · Jonesboro, ARNPI 1659323608

Payments from drug & device makers

$1,954,261in general payments, 2019–2025

Across 1,072 payments — averaging $1823.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$733K
  • Merck$408K
  • Eli Lilly$280K
  • AstraZeneca$198K
  • E.r. Squibb & Sons, L.L.C.$149K
  • Amgen$103K
  • plus $83K from 54 others
$10,541in research payments, 2019–2025

Across 5 payments — averaging $2108.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$11K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis87$732,828
Merck89$408,495
Eli Lilly27$280,105
AstraZeneca(2 entities)80$197,675
E.r. Squibb & Sons, L.L.C.57$149,226
Amgen47$102,882
GSK32$30,738
Incyte Corporation24$19,038
Radius Health, Inc.5$15,346
Bristol Myers Squibb19$4,063
Stemline Therapeutics Inc.1$2,533
Pfizer79$1,142
Johnson & Johnson(3 entities)58$873
Daiichi Sankyo Inc.33$713
AbbVie27$586
Sanofi30$568
Eisai Inc.25$533
Takeda Pharmaceuticals U.S.A., Inc.25$507
Regeneron Healthcare Solutions, Inc.13$395
Array Biopharma Inc14$306
Bayer17$296
Seagen Inc.13$281
EMD Serono, Inc.17$276
Exelixis Inc.14$270
Karyopharm Therapeutics Inc.5$247
Puma Biotechnology, Inc.15$233
Genentech USA, Inc.15$224
G1 Therapeutics, Inc.5$217
Sumitomo Pharma America, Inc.10$213
Lilly USA, LLC13$212
Gilead(2 entities)14$210
Kyowa Kirin, Inc.11$192
Ipsen Biopharmaceuticals, Inc10$188
Pharmacyclics LLC, An Abbvie Company9$184
Beigene USA, Inc.11$183
Pharmaessentia USA Corporation3$150
Astellas Pharma US Inc9$145
Boehringer Ingelheim6$138
Foundation Medicine, Inc.6$136
Deciphera Pharmaceuticals Inc.7$131
Acrotech Biopharma Inc.6$123
Myovant Sciences Inc.7$120
ADC Therapeutics America, Inc.7$116
Intera Oncology, Inc1$108
Sobi, Inc6$106
Rigel Pharmaceuticals, Inc.6$81
Beone Medicines USA, Inc.4$80
Global Blood Therapeutics, Inc.6$73
Tersera Therapeutics LLC4$70
Dova Pharmaceuticals5$66
Sanofi-aventis U.S. LLC1$60
AMAG Pharmaceuticals, Inc.4$57
Clovis Oncology, Inc.4$55
AVEO Pharmaceuticals, Inc.3$48
Apellis Pharmaceuticals, Inc.2$46
Iovance Biotherapeutics, Inc.2$45
Alnylam Pharmaceuticals Inc.3$43
Mirati Therapeutics, Inc.2$32
Servier Pharmaceuticals LLC2$32
Abiomed1$28

How this compares

$1,954,261 in reported general payments places this provider in the 95th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$216,724
Medicare patients
598
Services billed
3,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Jonesboro

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →